A user applied a homemade topical finasteride solution daily for 35 days, reducing hair shedding significantly with minimal side effects. They plan to continue for 90 days and will provide further updates.
17-alpha-estradiol may work for hair loss by inhibiting 5-alpha reductase, similar to finasteride. It might lower testosterone in the scalp, reducing DHT conversion.
Higher doses of dutasteride, such as 2.5mg, are more effective at reducing scalp DHT than 0.5mg, but are costly and inconvenient. A 1mg dose is considered a more affordable and practical option, though its efficacy is uncertain.
The user shared a 3.5-month hair regrowth update using finasteride, 5% topical minoxidil, micro-needling, and keto shampoo, along with lifestyle changes like reducing stress and improving diet. They encourage others to stay committed to their regimen despite initial slow progress.
The user experienced positive results in hair regrowth using 0.5mg dutasteride daily and 5% topical minoxidil, with no negative side effects except reduced chest/beard hair density. They plan to continue this routine for two years before possibly reducing the dutasteride dose.
The conversation discusses using tretinoin cream with minoxidil for hair loss treatment. Users suggest applying them separately to avoid reducing effectiveness.
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
After using finasteride for 7 months and dutasteride for 5 months, the user experienced a significant reduction in hair shedding and scalp itchiness. They advise patience with hair loss treatments and suggest focusing on a good haircut and reducing stress.
The user experienced worsening hair loss despite using finasteride, minoxidil, and microneedling. Suggestions included reducing microneedling frequency, switching to oral minoxidil, adding tretinoin, and considering dutasteride.
Dutasteride is less commonly prescribed for hair loss because it is not FDA-approved for this purpose, unlike finasteride, which is more accessible and preferred due to fewer side effects. Dutasteride may be more effective in reducing DHT but has a longer half-life and potentially more significant side effects.
OP is experiencing severe side effects from daily Minoxidil, Dutasteride, and Biotin use and is considering reducing Minoxidil to once or twice a week. A response advised seeing a doctor due to heart-related issues.
The conversation is about finding a solution for scalp inflammation related to AGA, with the user expressing frustration that Minoxidil and Finasteride do not address inflammation. The user has researched glucocorticoids and topical NSAIDs for reducing inflammation and seeks advice from specialists.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
Hair follicles don't truly die but become severely miniaturized. Treatments like finasteride, dutasteride, and minoxidil can help restore hair by providing nutrients and reducing harmful effects on hair roots.
The conversation is about the potential impact of RU58841 on male fertility, specifically regarding sperm concentration, total count, and motility. The user is curious about the likelihood of RU58841 reducing fertility based on its mechanism of action and comparisons to similar substances.
The user has been dealing with an oily scalp, seborrheic dermatitis, and hair loss for 18 months, using finasteride without improvement. Another user suggested dutasteride for reducing scalp oiliness.
Topical dutasteride may be effective for hair loss by staying in the scalp and minimizing bloodstream absorption, potentially improving hair results and reducing side effects. The user seeks advice on its effectiveness.
The conversation discusses the potential for high doses of dutasteride to completely inhibit scalp DHT and speculates whether this could cure baldness when combined with a topical antiandrogen. Specific dosages mentioned are 0.5 mg reducing scalp DHT by 55% and 2.5 mg by about 79%.
The conversation discusses managing estradiol problems during finasteride treatment. Suggestions include stopping finasteride every 3 months for 2-3 weeks or reducing the dosage.
John has experienced slight hair gains and stability over 20 years using Dutasteride, which is more effective than Finasteride in reducing scalp DHT and maintaining hair. Dutasteride at 0.5mg daily has a similar side effect profile to Finasteride, but at higher doses, it may increase the risk of sexual side effects.
The conversation discusses the use of 12.5mg cyproterone every other day for hair loss. There's a concern about reducing testosterone potentially increasing DHT and negatively affecting hair.
Using oral finasteride in combination with topical minoxidil and dermarolling for hair loss. Some users have reported significant regrowth when adding finasteride to their minoxidil routine, suggesting that reducing DHT levels may be a key factor in hair regrowth.
The conversation discusses why DHT (dihydrotestosterone) negatively affects scalp hair but promotes growth elsewhere on the body. Various opinions include genetic predispositions, differences in hair follicle reactions to DHT, and the potential role of Omega-3 in reducing inflammation and promoting hair health.
A 37-year-old man treated his hair loss with 0.5mg finasteride every other day and 5% minoxidil twice daily for 5 months, reducing finasteride from 1mg due to side effects. His hair improved significantly, with positive changes visible from all angles, and he experienced no more side effects after the dosage adjustment.
A 22-year-old male's 14-month hair loss treatment journey, starting with daily doses of dutasteride and minoxidil, then reducing dutasteride frequency, and finally switching to finasteride while maintaining daily minoxidil. Despite reduced libido, he's satisfied with his hair progress, started seeing results after 2 months, and believes finasteride is effective for maintenance.
A user shared their 21-month hair regrowth journey using oral Finasteride 1mg daily and Minoxidil 5% topical applications. Despite initial discouragement due to slow progress, they saw significant improvement, reducing the need for a hair transplant to minor fill-ins at the front hairline.
This user has had success with Minoxidil foam, achieving significant hair growth in three months without using finasteride or derma rolling. They are considering incorporating a DHT reducing strategy such as finasteride in the future.
A user shared their 9-month progress using RU58841 at 2% daily for hair regrowth, initially starting at 5% but reducing the dose due to early signs of gynecomastia, which has since mostly resolved. They achieved their goal of regrowing hair at the temples and hairline.
The effects of smoking cigarettes on DHT levels and its potential effect on hair loss, with some people sharing experiences in relation to their own hair loss. Various treatments for reducing or reversing hair loss were discussed, such as quitting smoking, minoxidil, finasteride and RU58841.
The conversation discusses hair loss treatments, specifically minoxidil, vitamin D supplements, and the potential impact of iron overload. The user experienced hair regrowth with high-dose vitamin D but faced hair thinning again after reducing the dosage, and is now exploring the role of iron overload in hair loss.